Eradicating the tumor "seeds": nanomedicines-based therapies against cancer stem cells.

Lin Li, Rui Ni, Dan Zheng, Lin Chen
{"title":"Eradicating the tumor \"seeds\": nanomedicines-based therapies against cancer stem cells.","authors":"Lin Li, Rui Ni, Dan Zheng, Lin Chen","doi":"10.1007/s40199-023-00456-0","DOIUrl":null,"url":null,"abstract":"<p><strong>Objectives: </strong>Cancer stem cells (CSCs), a small subpopulation of cells with high tumorigenesis and strong intrinsic drug resistance, exhibit self-renewal and differentiation abilities. CSCs play a crucial role in tumor progression, drug resistance, recurrence and metastasis,and conventional therapy is not enough to eradicate them. Therefore, developing novel therapies targeting CSCs to increase drug sensitivity and preventing relapse is essential. The objective of this review is to present nanotherapies that target and eradicate the tumor \"seeds\".</p><p><strong>Evidence acquisition: </strong>Evidence was collected and sorted from the literature ranging from 2000 to 2022, using appropriate keywords and key phrases as search terms within scientific databases such as Web of Science, PubMed and Google Scholar.</p><p><strong>Results: </strong>Nanoparticle drug delivery systems have been successfully applied to gain longer circulation time, more precise targeting capability and better stability during cancer treatment. Nanotechnology-based strategies that have been used to target CSCs, include (1) encapsulating small molecular drugs and genes by nanotechnology, (2) targeting CSC signaling pathways, (3) utilizing nanocarriers targeting for specific markers of CSCs, (4) improving photothermal/ photodynamic therapy (PTT/PDT), 5)targeting the metabolism of CSCs and 6) enhancing nanomedicine-aided immunotherapy.</p><p><strong>Conclusion: </strong>This review summarizes the biological hallmarks and markers of CSCs, and the nanotechnology-based therapies to kill them. Nanoparticle drug delivery systems are appropriate means for delivering drugs to tumors through enhanced permeability and retention (EPR) effect. Furthermore, surface modification with special ligands or antibodies improves the recognition and uptake of tumor cells or CSCs. It is expected that this review can offer insights into features of CSCs and the exploration of targeting nanodrug delivery systems.</p>","PeriodicalId":10961,"journal":{"name":"Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences","volume":"31 1","pages":"83-94"},"PeriodicalIF":0.0000,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10238364/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/s40199-023-00456-0","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/3/27 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Objectives: Cancer stem cells (CSCs), a small subpopulation of cells with high tumorigenesis and strong intrinsic drug resistance, exhibit self-renewal and differentiation abilities. CSCs play a crucial role in tumor progression, drug resistance, recurrence and metastasis,and conventional therapy is not enough to eradicate them. Therefore, developing novel therapies targeting CSCs to increase drug sensitivity and preventing relapse is essential. The objective of this review is to present nanotherapies that target and eradicate the tumor "seeds".

Evidence acquisition: Evidence was collected and sorted from the literature ranging from 2000 to 2022, using appropriate keywords and key phrases as search terms within scientific databases such as Web of Science, PubMed and Google Scholar.

Results: Nanoparticle drug delivery systems have been successfully applied to gain longer circulation time, more precise targeting capability and better stability during cancer treatment. Nanotechnology-based strategies that have been used to target CSCs, include (1) encapsulating small molecular drugs and genes by nanotechnology, (2) targeting CSC signaling pathways, (3) utilizing nanocarriers targeting for specific markers of CSCs, (4) improving photothermal/ photodynamic therapy (PTT/PDT), 5)targeting the metabolism of CSCs and 6) enhancing nanomedicine-aided immunotherapy.

Conclusion: This review summarizes the biological hallmarks and markers of CSCs, and the nanotechnology-based therapies to kill them. Nanoparticle drug delivery systems are appropriate means for delivering drugs to tumors through enhanced permeability and retention (EPR) effect. Furthermore, surface modification with special ligands or antibodies improves the recognition and uptake of tumor cells or CSCs. It is expected that this review can offer insights into features of CSCs and the exploration of targeting nanodrug delivery systems.

Abstract Image

消灭肿瘤 "种子":针对癌症干细胞的纳米药物疗法。
目的:癌症干细胞(CSCs)是一小部分细胞亚群,具有较高的肿瘤生成性和较强的内在耐药性,具有自我更新和分化能力。癌症干细胞在肿瘤进展、耐药性、复发和转移中起着至关重要的作用,传统疗法不足以根除它们。因此,开发针对 CSCs 的新型疗法以提高药物敏感性并防止复发至关重要。本综述旨在介绍针对和根除肿瘤 "种子 "的纳米疗法:从2000年至2022年的文献中收集并整理证据,使用适当的关键词和关键短语作为科学数据库(如Web of Science、PubMed和Google Scholar)中的搜索条件:纳米颗粒给药系统已被成功应用于癌症治疗中,以获得更长的循环时间、更精确的靶向能力和更好的稳定性。基于纳米技术的靶向 CSCs 策略包括:(1)利用纳米技术封装小分子药物和基因;(2)靶向 CSC 信号通路;(3)利用纳米载体靶向 CSCs 的特定标记物;(4)改进光热/光动力疗法(PTT/PDT);(5)靶向 CSCs 的新陈代谢;(6)加强纳米药物辅助的免疫疗法:本综述总结了 CSCs 的生物学特征和标记,以及杀死 CSCs 的纳米技术疗法。纳米颗粒给药系统是通过增强渗透性和滞留性(EPR)效应向肿瘤给药的合适手段。此外,用特殊配体或抗体进行表面修饰可提高对肿瘤细胞或造血干细胞的识别和吸收。希望这篇综述能为了解 CSCs 的特征和探索靶向纳米药物递送系统提供启示。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信